Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341904 | 0.83 | GAA (0.46) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL19341893 | 0.76 | GAA (0.43) | GAAALDH1A1TDP1KDM4EF2 | |
| SCHEMBL6625137 | 0.74 | GAA (0.69) | GAAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2596763 | 0.74 | ALDH1A1 (0.41) | GAAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL19341908 | 0.72 | GAA (0.48) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7109766 | 0.71 | GAA (0.42) | GAAALDH1A1MAPT | |
| SCHEMBL24181345 | 0.69 | GAA (0.83) | GAAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL16729201 | 0.69 | GAA (0.83) | GAAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL14560518 | 0.68 | TDP1 (0.76) | GAAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL10448207 | 0.68 | ALDH1A1 (0.43) | GAAALDH1A1TDP1KDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172393-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | MISSISSIPPI STATE UNIVERSITY | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172393-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | PNPO, PLPBP, PDXK | GAA 1631/4885MEN1 3175/4885KMT2A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.